A meta-analysis of multiple studies looked at whether Sativex (nabiximols) helps people with multiple sclerosis (MS) manage pain, spasticity, and disability. The analysis combined results from several trials to get a clearer picture of the drug's effects.
Researchers found that Sativex led to a significant reduction in pain intensity, measured on a numeric rating scale. Spasticity severity also dropped significantly. There was a modest but statistically significant improvement in disability, as measured by the Expanded Disability Status Scale.
The analysis did not report on side effects, serious adverse events, or how many people stopped taking the drug. It also did not list any limitations of the studies included. Because this is a meta-analysis, it combines existing data and does not provide new direct evidence from a single trial.
For people with MS, these findings suggest that Sativex may be an effective option for managing pain and spasticity. The benefit for disability was modest, so it should not be expected to dramatically change function. As always, talk to your doctor about whether this treatment is right for you.
